IRVINE, Calif., Sept. 30 /PRNewswire-FirstCall/ — Masimo
(Nasdaq:
MASI) announced today that a new multi-center study published
in the International Peer-Reviewed Academic Journal, Acta
Paediatrica, shows that a change in clinical practice with the use
of Masimo SET pulse oximetry technology led to a significant
reduction of severe Retinopathy of Prematurity (ROP)—a
devastating eye disease resulting in partial or complete
blindness—in premature newborns. The study also
confirmed that conventional pulse oximetry technology is not
effective in reducing ROP, even when clinical practice is changed
to reflect lowered oxygen saturation targets. (1)
ROP is the second leading cause of blindness in childhood in the
United States—affecting over 20% of premature babies. (2) A
major cause of ROP is the use of excess oxygen to treat respiratory
problems in premature babies, which stimulates abnormal vessel
growth within the eye. Although the use of pulse oximetry is
established as a standard-of-care technology for measuring oxygen
saturation and appropriately titrating oxygen administration to
prevent ROP, accuracy and reliability varies greatly by which pulse
oximetry technology is used. Masimo SET pulse oximetry
technology is clinically-proven to measure-through motion and low
perfusion, leading to accurate and reliable monitoring of oxygen
saturation in premature newborns. Although previous clinical
studies have shown a reduction in the incidence of ROP in premature
newborns when Masimo SET pulse oximetry is used in combination with
appropriate titration of oxygen administration, (3) (4) this is the
first published study showing a head-to-head comparison of Masimo
SET vs. another “next generation” pulse oximetry.
In the current study, researchers examined the role that SpO2
technology plays in the prevention of ROP in 571 high-risk
premature
‘/>”/>
SOURCE